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A ﬁrst  analysis  of a database  of  shared  preclinical  safety  data  for  1214  small  molecule
drugs  and  drug  candidates  extracted  from  3970 reports  donated  by  thirteen  pharmaceuti-
cal companies  for the eTOX  project  (www.etoxproject.eu) is  presented.  Species,  duration  of
exposure  and  administration  route  data  were  analysed  to  assess  if large  enough  subsets  of
homogenous  data  are  available  for building  in silico  predictive  models.  Prevalence  of  treat-
ment related  effects  for the different  types  of ﬁndings  recorded  were  analysed.  The  eTOX
ontology  was  used  to determine  the  most  common  treatment-related  clinical  chemistryData sharing
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and  histopathology  ﬁndings  reported  in the  database.  The  data  were  then  mined  to  evalu-
ate  sensitivity  of  established  in  vivo  biomarkers  for liver  toxicity  risk  assessment.  The  value
of  the  database  to inform  other  drug  development  projects  during  early  drug  development
is illustrated  by  a case  study.
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1. Introduction
Numerous chemicals are tested by the pharmaceutical
industry in order to perform a pre-clinical assessment of
clinical safety during the drug development process. Many
of these compounds fail during the early preclinical phase
and never make it into clinical trials or reach the market
[1,2]. Only rarely are the results of these preclinical studies
published. Even if the compound failed, there may  be ongo-
ing interest in related compounds which would preclude
revealing the chemistry to potential competitors. There
may  also be a lack of public interest in the failed compound
or a lack of enthusiasm from journals for publishing routine
toxicology reports. On the other hand, these studies repre-
sent a valuable data source for comparison with untested
drug candidates or impurities occurring during manufac-
turing,. It could also help to develop in silico predictive
models for endpoints which were previously not amenable
due to the scarcity of data. In addition, although archived
en access article under the CC BY license (http://creativecommons.org/
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is the number of animals recorded as displaying a particu-
lar effect and the total number of animals examined for
this effect, as well as the severity or grade is captured.K. Briggs et al. / Toxicol
n a fully traceable manner, study reports are rarely stored
n a format that supports data mining or the generation
f simple statistics. Some pharmaceutical companies have
ealised this hidden wealth in their archives and started
nternal work to improve retrievability of their report data.
owever, such initiatives have remained isolated and often
acked comprehensive data curation steps.
It would clearly be of beneﬁt to the industry to ana-
yse these data across multiple companies in order to learn
ow to avoid costly failures. By enhancing data availabil-
ty for compound comparison along with data mining to
uild more reliable in silico predictive models, these data
ould potentially lead to a more efﬁcient process for drug
evelopment and, of broader interest, a reduction in ani-
al  use (3Rs principle). However, extracting these data
rom the reports and building just such a database requires
onsiderable investment in terms of time and money.
In recognition of this, the European Innovative
edicines Initiative (IMI), a public-private partnership of
he European Union and the European Federation of Phar-
aceutical Industries and Associations (EFPIA), launched
 call for a project to be funded to achieve this goal of
ata sharing and building new in silico predictive mod-
ls. IMI  supports collaborative research projects and builds
etworks of industrial, small-to-medium enterprises
SMEs) and academic experts in order to boost phar-
aceutical innovation in Europe. Eleven expressions of
nterest from consortia of academic institutions and SMEs
ere submitted for the above-mentioned topic and sub-
equently evaluated by independent experts during 2008.
he project selected was  titled “Integrating bioinformat-
cs and chemoinformatics approaches for the development
f expert systems allowing the in silico prediction of toxi-
ities” and carries the acronym eTOX for electronic toxicity
3]. The eTOX project began January 2010 and as a result
f being awarded additional top-up funding is now sched-
led to complete its IMI  funding phase in December 2016.
otal funding over the seven years will amount to 18.7 MD  .
able 1 provides a full list of participants.
One key element of the eTOX project is the safe stor-
ge of the data extracted from legacy reports generated
y the EFPIA partners. Since the beginning of the project
t was identiﬁed that some data should and will remain
onﬁdential at least among the partners in the project;
ata safety did not only have to cover IT aspects but
lso safeguarding conﬁdentiality and intellectual prop-
rty protection. Lhasa Limited, a not-for-proﬁt, charitable
rganisation with a long history of sharing both conﬁden-
ial and non-conﬁdential data [4], was selected to be the
honest broker” hosting the harmonised toxicity database
ontaining both legacy data donated by the participat-
ng pharmaceutical organisations and complementary data
ollected from the public domain. A combination of legal
ontracts, physical access controls, software controls and
ntroduction of sensitivity levels (see Fig. 1) were deﬁned in
rder to safeguard sensitive data shared within the project.
ata classiﬁed as Non-Conﬁdential Shared Data are acces-
ible to all eTOX project participants but are not at this stage
vailable for sharing outside the project. Public Data have
lso been gathered for the purposes of the project and these
ata are accessible outside the consortium. Data classiﬁedorts 2 (2015) 210–221 211
as Conﬁdential Shared Data are only accessible to the data
owner and the honest broker. Model developer partners
within the eTOX consortium have to agree a secrecy agree-
ment with the data owner in order to mine these data.
In-house Data are data that are only accessible by the data
owner although not shared with the consortium it is recog-
nised as a category as it could be used to validate eTOX
models.
Relevance of the covered chemical space and data qual-
ity are essential if the goal of accurate in silico toxicity
prediction is to be achieved. There are a number of initia-
tives that are sharing data for toxicity prediction purposes,
for example ToxCast2 and COSMOS,3 but these are not
focussed on drug-like chemical space. The legacy data
donated includes studies on compounds that have become
drugs and many more chemicals that have failed to reach
the market whether for safety issues or for other reasons.
They are therefore, drug-like and so represent the best pos-
sible chemical space for predicting toxicity of future drugs.
In addition, the majority of studies will have been con-
ducted in accordance with International guidelines, such as
OECD or ICH, and many of them also adhering to the prin-
ciples of good laboratory practice (GLP). As a consequence
the studies can be considered to be of high quality [5].
After setting up the legal and IT infrastructure, EFPIA
companies began to identify the study reports which
should be extracted and included in the database. Although
the scope of the eTOX project is to ultimately cover all
in vivo study types conducted during drug development,
the initial focus was put on routine toxicity studies such
as the dose range ﬁnding studies, maximum tolerated dose
studies, the pivotal studies (mainly 28-day toxicity stud-
ies) conducted to support ﬁrst time in man  (FTIM) and
the chronic studies aimed at supporting later stage clin-
ical development. The reason for this prioritisation was
because they represent the key studies for dose setting
and safety assessment prior to FTIM and because it was
expected that these study types would occur in the archives
with highest frequencies.
EFPIA companies found that the majority of these stud-
ies were archived as paper ﬁles (paper, scanned PDF or
PDF/A). After internal legal clearance the manual data
extraction was started. Fig. 2 displays the rates at which
the study reports were identiﬁed, cleared, extracted and
included into the Vitic Nexus database management sys-
tem which is maintained by Lhasa Limited [6].
The eTOX database contains entries for all endpoints
measured or determined during a systemic toxicity study.
Data are captured for each dose and sex group evaluated in
the study plus the control group and all time points where
measurements or observations were taken, whether they
show an increase, decrease or are unchanged.
For qualitative data such as clinical signs, gross necropsy
and histopathology the incidence in each dose group, that2 http://www.epa.gov/ncct/toxcast/ (accessed 16.09.14).
3 http://www.cosmostox.eu/home/welcome/ (accessed 16.09.14).
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Table 1
Full list of participants in the eTOX project.
Private partners Public partners
EFPIA companies Academic institutions
AstraZeneca Erasmus Universitair Medisch Centruma
Bayer HealthCare European Molecular Biology Laboratory
Boehringer Ingelheim Fraunhofer Gesellschafta
F. Hoffmann-La Roche Fundació Institut Mar  d’ Investigacions Mèdiques
GlaxoSmithKline Fundación Centro Nacional de Investigaciones Oncológicas Carlos III
H.  Lundbeck Liverpool John Moores University
Janssen Pharmaceutical Technical University of Denmark
Laboratorios del DrEsteve Universitat Politècnica de Valenciaa
Les Laboratoires Serviera Universität Wien
Novartis Pharma University of Leicestera
Pﬁzer Ltd. Vrije Universiteit Amsterdam
Sanoﬁa SMEs
UCB Pharma Chemotargets SL
Inte:Ligand GmbH
Lead Molecular Design SL
Lhasa Limited
Molecular Networks GmbH
earch M aSYNAPSE Res
Organisations leading the project are depicted in bold.
a Organisations that joined eTOX after its inception.
For quantitative data such as clinical chemistry, haematol-
ogy, haemostasis, urinalysis and organ weights the average
value for each dose group, standard deviation and units are
captured along with the average fold change where this is
reported and whether the value was identiﬁed as increased
or decreased. For both qualitative and quantitative data if
the study report records a judgement call on whether the
ﬁnding is considered treatment-related or not, then this is
also captured in the database along with the ﬁnding.
A single compound in the eTOX database can have
many studies associated with it. These studies are likely
to be performed in different species and strains, for dif-
ferent lengths of time with sometimes the compound
administered by different routes. This presents a challenge
when using the data to build in silico models since these
Fig. 1. Data sensitivity classiﬁcationanagement Partners, SL
factors can all inﬂuence the toxicity observed. In addition,
each study will have multiple values for a speciﬁc end-
point representing each time point at which the data were
recorded during the study and the different dose and sex
groups. For the purposes of modelling, this information
is best condensed down to a single value per chemical,
combining results from all studies, dose groups and time
points for that chemical. The judgement calls included in
the database are useful in this respect as they can be used
to derive a binary classiﬁcation where positive ﬁndings
are those ﬁndings identiﬁed in the original study report
as treatment-related and negative ﬁndings are all ﬁndings
not identiﬁed as treatment-related.
Paramount for the usability of the database was the
establishment of ontologies [7] for the numerous terms
s within the eTOX project.
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Fig. 2. Chronological progress of number and s
Table 2
Number of data records included in the 2014-1 eTOX non-conﬁdential
shared database. Data for compounds that are conﬁdential where the
study data are classiﬁed as non-conﬁdential are included but without any
structural information.
Conﬁdential compounds Non-
conﬁdential
compounds
Non-
conﬁdential
studies
u
e
p
c
w
m
d
a
s
d
v
p
r
1
c
c477 737 3393
sed throughout the reports. Many of these terms have
volved over time, across different companies, and in the
ublic literature. Often the EFPIA companies did not apply
onsistent terms in their reports. Therefore the decision
as taken to extract the verbatim terms and to then
ap  them retrospectively to a common ontology being
eveloped within the project by a curation team. The hier-
rchical structure of the ontology also allows ﬁndings to be
ummarised at different levels allowing data captured at
ifferent levels of granularity (e.g. “gastrointestinal tract”
ersus “colon”) to be used together.
In total, the 13 participating EFPIA pharmaceutical com-
anies have already donated data extracted from 3970
eports to the project and the latest release includes
214 drugs or drug candidates (Table 2). The eTOX non-
onﬁdential shared database is already used within several
ompanies to compare new drug candidates to previouslytatus of study reports as of April 2014.
tested compounds [8]. In addition to such comparisons,
the database should now have achieved a size to support
deeper analyses of potential underlying correlations and
for modelling. As a ﬁrst step, we  therefore performed a
systematic analysis of distribution of various parameters
which are reported in this manuscript.
2. Method
The data analysis that follows is based on the 2014-
1 version of the eTOX non-conﬁdential shared database
released on the 8th April 2014. This incorporates only
the non-conﬁdential shared data. If the compound is con-
sidered conﬁdential but the study data are classiﬁed as
non-conﬁdential these data are also included in the release
but without any structural information.
KNIME 2.8.0 and Microsoft Excel 2010 were used to
perform the data analysis. Database Reader and GroupBy
nodes were used to determine how the eTOX non-
conﬁdential shared database was  split in terms of species,
(Fig. 3), duration of exposure (Fig. 4) and administration
route (Fig. 5). To create the pie charts, preferred terms that
were assigned in the ontology for species and route were
used; exposure duration values were assigned to discrete
intervals (bins). As the toxicity observed will be affected by
these parameters it is important that large enough subsets
of homogenous data are available for building models.
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Fig. 3. Species distribution in eTOX 2014-1 database (number of studies).
 eTOX 2Fig. 4. Study duration distribution inEven though many of the extracted reports reﬂect
summarised studies performed according to guidance
documents or standard operation procedures, it became
clear, that the heterogeneity of terms used for organs,
Fig. 5. Administration route distribution in eTO014-1 database (number of studies).tissues and ﬁndings was  extremely high. This heterogene-
ity together with the resulting high numbers of entries
describing identical concepts clearly limits the value of the
database in terms of query function, statistical analysis and
X 2014-1 database (number of studies).
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nter-operability. It was therefore key to develop ontolo-
ies for mapping of these terms to a smaller number of
referred terms. The consortium ontologies were based on
xisting ones, such as the Adult Mouse Anatomy Ontology,4
nd are being developed with other initiatives in mind,
uch as CDISC-SEND5 and INHAND [9]. Many cross refer-
nces were introduced to maximise interoperability.
With ﬁndings in the database mapped to preferred
erms it was possible to analyse the eTOX non-conﬁdential
hared data for the most frequent positive ﬁndings by
ounting the number of compounds which had these
ndings ﬂagged as treatment-related in the study report
Fig. 6). We  also investigated the number of negative ﬁnd-
ngs by counting the number of compounds where these
ndings were not ﬂagged as treatment-related in the study
eport; as for modelling purposes both negative and pos-
tive ﬁndings are needed. It is important that those areas
ith the majority of positive ﬁndings are mapped to the
ntologies in order to allow grouping of ﬁndings at the
referred term level.
The majority of verbatim terms for organs and clini-
al chemistry parameters have already been mapped to
hese preferred terms in the eTOX ontology (coverage
or 2014-1 release at 98% and 80%, respectively). There-
ore, we investigated the frequency of organs associated to
reatment-related histopathology (Fig. 7) and treatment-
elated changes in clinical chemistry parameters (Fig. 9).
Since mapping of histopathology terms to the common
ntology is progressing but as yet incomplete (coverage for
014-1 release at 67%), unmapped terms pending curation
ere not taken into account for the analysis of frequency
f treatment-related histopathology (Fig. 8).
Unsurprisingly, liver was identiﬁed as the most com-
on histopathology ﬁnding in the database, so we decided
o investigate how predictive the different clinical chem-
stry parameters were of treatment-related histopathology
n the liver. Treatment-related refers to the expert call cap-
ured from the original report and not one generated by
 retrospective analysis of the raw data. See Table 3 for
eﬁnitions used for this analysis.
Having determined TN, FN, TP and FP values we  then
sed these to calculate Matthews correlation coefﬁcient
MCC) and statistical signiﬁcance (two tailed Fisher exact
est). The clinical chemistry parameters with a signiﬁcance
f p < 0.001 were then ranked using MCC  (Table 5).
Rules of thumb to assess human drug induced liver
njury (DILI) such as Hy’s Law [10] utilise a combination
f changes, speciﬁcally a 3 fold rise in alanine aminotrans-
erase (ALT) or aspartate aminotransferase (AST) above the
pper limit of normal (ULN) accompanied by total biliru-
in 2xULN. Alkaline phosphatase (ALP) must also be normal
hich would exclude cholestatic effects where both biliru-
in and ALP are expected to increase. Therefore we also
nvestigated whether predictivity was improved by com-
ining the most predictive of the parameters from the
4 http://www.obofoundry.org/cgi-bin/detail.cgi?id=adult mouse
natomy (accessed 16.09.14).
5 http://evs.nci.nih.gov/ftp1/CDISC/SEND/SEND%20Terminology.
tml#CL.C650 (accessed 16.09.14).orts 2 (2015) 210–221 215
previous analysis, with the other top 10 changes in clinical
chemistry. Obviously if both parameters were negative this
should result in a combined negative and if both were posi-
tive this should be a combined positive but where there was
disagreement we  had a choice of emphasising either neg-
ative or positive predictions. We  decided to explore both
options for the effects on number of TN, FN, TP and FP as
well as MCC  values (Table 6).
3. Results and discussion
The eTOX 2014-1 database was  analysed for distribu-
tion by species, duration of exposure and administration
route and by frequency of different types of treatment-
related ﬁndings. The eTOX ontology was  used to determine
the most common treatment-related clinical chemistry and
histopathology ﬁndings reported in the database. The data
were then mined to evaluate sensitivity of established in
vivo biomarkers for liver toxicity. The value of the database
for the mechanistic assessment of toxic effects of early drug
candidates is illustrated by a case study.
3.1. Analysis by species
Analysis of how the eTOX non-conﬁdential shared
database is split by species reveals that the majority of the
data are extracted from rat studies, but that other species
including dog and monkey are also well represented.
3.2. Analysis by study duration
The split by study duration illustrates that a wide variety
of studies are included in the eTOX non-conﬁdential shared
database but that donations have been focused on shorter
studies of up to 4 weeks in duration.
Besides study duration we  also analysed percentage
breakdown for each of the different study types in terms
of study quality assessment. The majority of the short term
studies (<20 days) are described as non-GLP, GLP in part
or have no information on study quality (66%), whereas
the subacute studies (20–35 days) are predominantly GLP
(77%).
3.3. Analysis by administration route
In terms of administration route, the vast majority
of studies were performed via the oral route (gavage or
addition to food or drinking water), which reﬂects the
intended dosage form for humans. However, a consider-
able variety of different routes are represented in the eTOX
non-conﬁdential shared database with intravenous being
the next most common route.
3.4. Frequency of different types of treatment-related
ﬁndingsDue to the heterogeneity of report protocols, not all
ﬁnding types are investigated as part of this study. The
most prevalent analysis is histopathology, of the 1214 com-
pounds included in the 2014-1 release, 1200 (99%) have
216 K. Briggs et al. / Toxicology Reports 2 (2015) 210–221
Fig. 6. Number of positive versus negative compounds associated with the different types of ﬁndings in the eTOX 2014-1 database. Positive compounds:
compounds with these ﬁndings ﬂagged as treatment related. Negative compounds: compounds with these ﬁndings that are not ﬂagged as treatment
related.
elated h
poundsFig. 7. Top 10 organs based on the number of compounds with treatment-r
compounds with these ﬁndings ﬂagged as treatment related. Negative comhistopathology data. The analysis of the frequency of over-
all treatment-related ﬁndings shows that the majority of
these are reported under histopathology with 732/1200
(61%) compounds ﬂagged as positive. This is followed
Fig. 8. Top 10 histopathology ﬁndings based on the number of compounds with tistopathology ﬁndings in the eTOX 2014-1 database. Positive compounds:
: compounds with these ﬁndings that are not ﬂagged as treatment related.by clinical chemistry with 528/1081 (49%) positive com-
pounds although organ weights and clinical signs are of a
similar magnitude. In terms of the ratio of positive versus
negative compounds; histopathology has overall more
hese ﬁndings ﬂagged as treatment-related in the eTOX 2014-1 database.
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Fig. 9. Top 10 changes in clinical chemistry based on the number of compounds with these ﬁndings ﬂagged as treatment-related in the eTOX 2014-1
database. Positive compounds: compounds with these ﬁndings ﬂagged as treatment related. Negative compounds: compounds with these ﬁndings that
are  not ﬂagged as treatment related.
Table 3
Deﬁnitions used for true positive, false positive, false negative and true negative.
Liver histopathology
exists and is
treatment-related
Liver histopathology
exists and is not
treatment-related
p
e
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tClinical chemistry parameter exists and is treatment-related 
Clinical chemistry parameter exists and is not treatment-related
ositive ﬁndings whereas clinical chemistry has roughly
qual numbers of positive and negative ﬁndings.
.5. Frequency of treatment-related histopathology
ndings
Investigating the histopathology ﬁndings further
eveals that out of the 229 distinct locations included in
he eTOX non-conﬁdential shared database, liver is the
ost common organ to show drug-related effects with
03 positive compounds. This is followed by spleen as the
econd most common organ with 238 positive compounds
lthough kidney and thymus are of a similar magnitude.
he list of organs investigated per study vary, for example
f the 1200 compounds having histopathological ﬁndings
ssociated with them, only 949 (79%) have data for the
iver.
We hypothesised that the high ranking of some of these
rgans, e.g. thymus, could be the consequence of toxicity
n other organs where the ﬁrst organ is the primary target
nd the thymus a secondary target [11]. In order to assess
his, we removed ﬁndings where the lowest dose associ-
ted with a treatment-related ﬁnding in the thymus was
igher than the overall lowest dose for all histopathology
ndings in the study. Using this method, the number of pos-
tive compounds drops from 236 to 136. Looking at which
rgans are associated most frequently with treatment-
elated ﬁndings in the thymus then of these 136 substances
4 also showed effects in the liver and 73 in spleen.We also considered the effects on this ranking due to
he distribution of study types within the database. Since
lmost half of the studies are of short duration (<20 days)
his might skew the results to organs more exposed toTrue positive (TP) False positive (FP)
False negative (FN) True negative (TN)
the drug or more susceptible to toxicity in the short term
and underestimate organs where pathology develops over
longer periods of time. We  therefore reanalysed the data
for each study type to see whether there were any dif-
ferences. Liver remained as the number one ﬁnding for all
study types and both spleen and kidney remained ranked
in the top 10 (Table 4).
In the case of pathology terms mapped to the eTOX
ontology the top 10 ﬁndings observed are located in 5
organs: kidney, liver, lung, spleen and thymus, all of which
were among the top 10 organs identiﬁed in the previous
analysis. Unsurprisingly, hepatocyte hypertrophy is the top
ﬁnding reported followed by increased hematopoiesis in
the spleen.
However since the verbatim pathology terms have not
been fully mapped to the ontology (coverage currently
at 67%) these should be considered preliminary ﬁndings.
When dealing with data from 13 companies, produced
by hundreds of pathologist, a great deal of normalisation
is needed in order to be able to do cross study analysis
efﬁciently. It is a work in progress with a core team of
pathologists from four distinct companies meeting every
two weeks along with connections to controlled vocab-
ularies (standards like INHAND and SEND terminology
initiatives). As of 13th March 2014 the histopathology ﬁnd-
ing ontology contained 848 preferred terms and 18,808
synonyms.
3.6. Frequency of treatment-related clinical chemistry
ﬁndings
On analysing clinical chemistry the most prevalent ﬁnd-
ing here is treatment-related changes in ALT with 211
218 K. Briggs et al. / Toxicology Reports 2 (2015) 210–221
Table 4
Top 10 organs for each study type based on the number of compounds with treatment-related histopathology ﬁndings in the eTOX 2014-1 database.
Rank <20 days 20–35 days 36–81 days 82–10 days >101–364 days >365 days
1 Liver Liver Liver Liver Liver Liver
2  Thymus Kidney Thymus Adrenal gland Kidney Spleen
3  Spleen Spleen Lung Lung Adrenal gland Testis
4  Kidney Thymus Mesenteric lymph node Spleen Thymus Gall bladder
5  Lung Lung Spleen Thymus Lung Kidney
6  Stomach Adrenal gland Bone Marrow Testis Testis Ovary
7  Adrenal gland Mesenteric lymph node Epididymis Kidney Spleen Mammary gland
8  Mesenteric lymph node Ovary Kidney Stomach Mesenteric lymph node Adrenal gland
9  Duodenum Stomach Ovary Skin Ovary Brain
10  Heart Thyroid gland Vagina Thyroid gland Stomach Heart
Table 5
Top 10 clinical chemistry changes predicting histopathology in the liver.
Clinical chemistry parameter TP FP FN TN MCC  Sensitivity Speciﬁcity
Alanine aminotransferase (ALT) 135 64 206 392 0.2921 39.6 86.0
Alkaline phosphatase (ALP) 106 43 217 371 0.2771 32.8 89.6
Cholesterol 124 61 174 303 0.2755 41.6 83.2
Aspartate aminotransferase (AST) 93 49 226 374 0.2211 29.2 88.4
Bilirubin 53 27 198 322 0.1941 21.1 92.3
Triglycerides 84 54 172 261 0.1820 32.8 82.9
Albumin 99 61 223 306 0.1669 30.7 83.4
Creatinine 59 33 247 374 0.1650 19.3 91.9
Urea  61 43 199 301 0.1438 23.5 87.5
Protein 92 66 226 311 0.1358 28.9 82.5
Table 6
Effect of combining clinical chemistry changes on predicting histopathology in the liver.
Clinical chemistry parameter FP TP TN FN MCC  Sensitivity Speciﬁcity
ALT + alkaline phosphatase 53 168 379 180 0.3972 48.3 87.7
ALT  + creatinine 44 157 384 192 0.3942 45.0 89.7
ALT  + cholesterol 74 182 378 168 0.3790 52.0 83.6
ALT  + bilirubin 47 150 393 196 0.3742 43.4 89.3
ALT  + aspartate aminotransferase 54 149 389 194 0.3541 43.4 87.8
ALT  + triglycerides 72 168 377 180 0.3486 48.3 84.0
ALT  + albumin 70 166 379 183 0.3475 47.6 84.4
374 
373 
392 ALT  + urea 59 155 
ALT  + protein 72 167 
ALT  64 135 
positive compounds, conﬁrming the liver as a top contribu-
tor to compound toxicities. Effects on cholesterol, albumin
and protein are also common. AST and ALP also make
the top 10 but not bilirubin. Considering the preponder-
ance of histopathology effects in the liver it is perhaps
not surprising that, with the exception of potassium, these
are all indicators of hepatic injury [12]. Treatment-related
changes in potassium could be due to gastrointestinal dis-
orders or damage to the kidney [13].
3.7. Biomarkers for liver toxicity
Bilirubin does not make the top 10 most com-
mon treatment-related clinical chemistry ﬁndings in the
database, however, it does make the top 10 for clin-
ical chemistry changes predictive of treatment-related
histopathology ﬁndings in the liver. The table below reports
the values for true and false positives and negatives for the
top 10 statistically signiﬁcant parameters ranked by MCC
value (Table 5).
Combining ALT, the most predictive of these parame-
ters, with the other clinical chemistry parameters included192 0.3457 44.7 86.4
182 0.3427 47.9 83.8
206 0.2921 39.6 86.0
in the top 10, so that if one is positive and the other neg-
ative this is treated as a combined negative, increased
the number of true and false negatives and reduced true
and false positives. However in terms of MCC  values none
of the combined parameters performed better than ALT
alone.
By contrast higher MCC  values were obtained if ALT
was  combined with other parameters so that if one is pos-
itive and the other negative it is considered a combined
positive (Table 6). The increase in MCC  was accompanied
by increased true positives and decreased false negatives.
False positives were also decreased when combining ALT
with ALP, AST, bilirubin, creatinine and urea. However, only
the combination of ALT and bilirubin increased true nega-
tives.
3.8. Case study for evaluation and assessment of toxic
effects of early drug candidatesBesides data mining the database for the sensitivity of
established in vivo biomarkers as described above it can
also have a value for the mechanistic assessment of toxic
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Fig. 11. Percentage of compounds associated with haematological ﬁnd-Fig. 10. Investigated compounds for whic
ffects of early drug candidates This shall be illustrated by
he following example.
For the investigation of potential drug candidates for a
arget related to the prostaglandin E receptor, two com-
ounds were investigated in a short term rat toxicity study
see Fig. 10).
Both compounds resulted in the following haematolog-
cal ﬁndings:
decrease in erythrocytes and haemoglobin
increase in reticulocytes
increase in thrombocytes
increase in leucocytes and neutrophils
Since both compounds contain a benzoic acid moiety,
edicinal chemists asked if these rather speciﬁc haema-
ological ﬁndings could be related to the substructure and
hether removal of this substructure could alleviate these
ndings, prompting a search of the eTOX database for evi-
ence to support this hypothesis.
In a ﬁrst step the prevalence of the benzoic acid moi-
ty was determined in the whole dataset. In a subsequent
uery the number of compounds containing the benzoic
cid moiety and concomitantly causing any kind of haema-
ological ﬁndings was determined.
The results of these queries are displayed in Fig. 11.
Overall the free benzoic acid moiety occurred in only
.1% of all queried compounds. Only 18% of the com-
ounds with this structural feature were associated with
he speciﬁed treatment-related haematological ﬁndings,
hile 26% of all queried compounds had treatment-
elated haematological ﬁndings. It is therefore concluded
hat there is no evidence that the benzoic acid moiety
s over-represented in the group of compounds with
Fig. 12. Screenshot of the multi-parameter search for ﬁndings observed inings. Upper pie chart: for all compounds in the eTOX 2014-1 database.
Lower pie chart: the 1.1% of compounds containing a benzoic acid moiety.
treatment-related haematological ﬁndings, which speaks
against a causal relationship of this substructure.
In a second step the database was queried for the occur-
rence of the combined ﬁndings; decrease in haemoglobin
and concomitant increase in both platelets and reticulo-
cytes (Fig. 12).
 the short term toxicity studies with the relevant drug candidates.
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Table 7
Selected compounds of the multi-parameter search for decrease in haemoglobin and concomitant increase in both platelets and reticulocytes. The two
compounds show both a structural similarity with the early candidates depicted in Fig. 10 and a pharmacological mode of action related to the described
development project.
Pharmacological
action
Structure image Species Strain Sex Vehicle Dosage
EP1 receptor
antagonist
Rat Alpk:APfSD
Wistar derived
Male and
female
0.5% hydroxypropyl
methylcellulose in 0.1%
aqueous polysorbate
80
0 mg/kg; 5 mg/kg;
50 mg/kg; 2000 mg/kg
reduced to 1000 mgkg
on day 18
EP1  receptor
antagonist
Rat AP rats
(Alpk:APfSD
strain, Wistar
derived)
Female 0.5% (w/v) HPMC
solution containing
0.1% (w/v) polysorbate
80
0 mg/kg/day;
50 mg/kg/day;
300 mg/kg/day;
1200 mg/kg/day
EP1  receptor
antagonist
Rat AP rats
(Alpk:APfSD
strain, Wistar
derived)
Male 0.5% (w/v) HPMC
solution containing
0.1% (w/v) polysorbate
80
0 mg/kg/day;
50 mg/kg/day;
300 mg/kg/day;
1000 mg/kg/day
EP1  receptor
antagonist
Dog Beagle Male and
female
0.5% (w/v)
hydroxylpropyl
methylcellulose
(HPMC) solution
0 mg/kg; 75 mg/kg;
150 mg/kg; 300 mg/kgThe query resulted in a list of 20 compounds. Upon
inspection of these 20 hits, two compounds attracted
speciﬁc attention (see Table 7) not only because they
showed a structural similarity to the compounds under
question, though the benzene ring was replaced by a
pyrazin, but also because the information on the phar-
macological action of the compound pointed to a related
target (EP1 receptor antagonist). In addition, the query also
revealed that the ﬁndings are not restricted to rat studies
but were also observed in dogs, i.e. the observed effects do
not seem to be species-speciﬁc and the weight of evidence
points towards a pharmacodynamic action rather than a
pure chemistry-related toxicity.
In summary, the database delivered valuable con-
tributions to this development project with regard to
chemistry-related toxicity, species-speciﬁcity of observed
toxic effects and selectivity of the pharmacodynamic action
of the compound without any additional animal experi-
ments.
4. Conclusion
The eTOX database is potentially the largest available
repository of in vivo repeat dose toxicity data derived from
industry drug discovery activities. Its development means
that this vast wealth of legacy data previously only acces-
sible to the respective data owners can now be more fully
exploited. By collaboratively sharing these data, it is nocontaining 0.1% (w/v)
aqueous polysorbate
80
longer a seemingly impossible task to answer simple ques-
tions such as ‘what is the most common drug-induced liver
toxicity across all studies?’; in this present analysis hep-
atocyte hypertrophy. In the future, many more complex
questions will be answered using this valuable toxicolog-
ical resource. The description of a ﬁrst use case shows
how the database can be meaningfully applied to answer
questions raised during early drug development without
performing additional animal studies.
The initial focus of data collection by pharmaceutical
companies participating in the project has been sys-
temic toxicity, repeat dose studies in preclinical species.
However during the course of the project integra-
tion with existing clinical databases and extraction of
data from safety pharmacology, pharmacokinetics, phar-
macodynamics, reproductive-developmental toxicity and
carcinogenicity studies is planned, along with use of all
these data to build robust multiscale and multilevel pre-
dictive models to support risk assessment. The intention is
not to create a frozen system with static data and models
but to continue data incorporation beyond the end of the
project and drive modelling practice. Drug development
data are becoming increasingly available to the commu-
nity and we do believe precompetitive exchanges should
become the norm in the future. As part of the discussion on
sustainability the consortium is also considering how the
database and models integrated into eTOXsys, the predic-
tive system developed within the eTOX consortium, might
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